Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medicago Inc.
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.
Hanmi is accelerating development of a plant-derived COVID-19 vaccine with Bioapp after successful early, the forming part of the leading South Korean pharma group’s post-pandemic business vision, which includes 'green biotech'.
A round-up of developments in the COVID-19 vaccine field from Moderna, Fosun, Merck & Co and Medicago and more.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies